This construct, an AAV9 vector carrying SMN1 complementary recombinant DNA, can cross the brain–blood barrier, produces a sustained expression of SMN protein and prolongs survival of treated SMA-mice [42,43,44]. Here, SMN2 is linked to proximal spinal muscular atrophy.